real-time news and commentary for investors
Wednesday, Jun 6
2012, 4:13 PM
Achillion Pharmaceuticals (ACHN) announces the resignation of its Senior VP of Clinical...
Achillion Pharmaceuticals (ACHN) announces the resignation of its Senior VP of Clinical Development and Chief Medical Officer, Elizabeth Olek, effective June 18. Milind Deshpande, Ph.D., President of R&D and Chief Scientific Officer, will assume oversight of all ongoing and planned clinical trials. The resignation comes at a key time as the company moves into important clinical trials for its protease inhibitor, ACH-1625, and second-generation NS5A inhibitor, ACH-3102, later this year. Shares -4.2% AH.